SMARCA2 and neoplasm: A variety of neoplasms have been discovered to have genomic alterations and loss of immunohistochemical (IHC) expression of chromatin remodelers ARID1A (BAF250A), SMARCA2 (BRM), SMARCA4 (BRG1), and SMARCB1 (INI1) [4].